EHA Library - The official digital education library of European Hematology Association (EHA)

ENDOCRINE DISORDERS IN HODGKIN LYMPHOMA SURVIVORS
Author(s): ,
Mariia Voytko
Affiliations:
Hematology,Novosibirsk State Medical University,Novosibirsk,Russian Federation
,
Tatyana Pospelova
Affiliations:
Hematology,Novosibirsk State Medical University,Novosibirsk,Russian Federation
,
Vadim Klimontov
Affiliations:
endocrinology,Novosibirsk State Medical University,Novosibirsk,Russian Federation
Jana Shebunyaeva
Affiliations:
Hematology,Novosibirsk State Medical University,Novosibirsk,Russian Federation
EHA Library. Voytko M. 06/09/21; 325536; EP778
Mariia Voytko
Mariia Voytko
Contributions
Abstract
Presentation during EHA2021: All e-poster presentations will be made available as of Friday, June 11, 2021 (09:00 CEST) and will be accessible for on-demand viewing until August 15, 2021 on the Virtual Congress platform.

Abstract: EP778

Type: E-Poster Presentation

Session title: Hodgkin lymphoma - Clinical

Background

Current treatment options for Hodgkin's lymphoma are mostly effective, but may have a negative pronounced damaging effect on some organs.  Long-term effects of antitumor therapy in HL survivors include secondary cancers, cardiovascular and pulmonary disorders, neurological complications, and endocrine and gonadal dysfunctions.  Endocrine late effects with hormonal disturbances, could have many physical and social consequences for HL survivors.

Aims
To assess the prevalence and risk factors of endocrine disorders  in HL survivors. 

Methods
The study evaluated the functioning of the endocrine system in 160 patients with HL (55 male and 105 female) aged 18 to 65 years after chemoradiotherapy. The clinical examination included a biochemical analysis of blood, test of serum hormones (THS, T3, free T4, PTH, FSH, LH, free testosterone, DHEA-S, SHBG) by ELISA, BMD was assessed by dual-energy X-ray absorptiometry.

Results

The structure of endocrine pathology in patients with HL included primarily hypothyroidism (25%), hyperparathyroidism (15,6%) and hypogonadism (29% of male and 25.3% of female). Dysfunction of the hypothalamic-pituitary-thyroid axis occurred significantly more often in patients after combined chemoradiotherapy than in patients receiving chemotherapy only (χ2=9,4, р=0,002). We found that increased levels PTH was negatively correlated with BMD in the lumbar spine (r = -0,74, p = 0,00002) and in the femoral neck (r = -0,66, p = 0,0003). The men with HL had lower free testosterone than controls (p=0,04). However, LH and FSH levels in male with HL were elevated: p = 0,0004 and p = 0,04, respectively. Women of reproductive age with HL had higher levels of LH in the luteal phase (p = 0,05) and a higher levels of FSH in the follicular phase (p = 0,02) than controls.

Conclusion

The high prevalence of endocrine disorders in HL survivors demonstrates the necessity to develop screening programs for early treatment of endocrine pathology in patients with HL, as well as the participation of endocrinologists in the follow-up and treatment of this category of patients.                                                                                                                                  

Keyword(s): Hodgkin's lymphoma

Presentation during EHA2021: All e-poster presentations will be made available as of Friday, June 11, 2021 (09:00 CEST) and will be accessible for on-demand viewing until August 15, 2021 on the Virtual Congress platform.

Abstract: EP778

Type: E-Poster Presentation

Session title: Hodgkin lymphoma - Clinical

Background

Current treatment options for Hodgkin's lymphoma are mostly effective, but may have a negative pronounced damaging effect on some organs.  Long-term effects of antitumor therapy in HL survivors include secondary cancers, cardiovascular and pulmonary disorders, neurological complications, and endocrine and gonadal dysfunctions.  Endocrine late effects with hormonal disturbances, could have many physical and social consequences for HL survivors.

Aims
To assess the prevalence and risk factors of endocrine disorders  in HL survivors. 

Methods
The study evaluated the functioning of the endocrine system in 160 patients with HL (55 male and 105 female) aged 18 to 65 years after chemoradiotherapy. The clinical examination included a biochemical analysis of blood, test of serum hormones (THS, T3, free T4, PTH, FSH, LH, free testosterone, DHEA-S, SHBG) by ELISA, BMD was assessed by dual-energy X-ray absorptiometry.

Results

The structure of endocrine pathology in patients with HL included primarily hypothyroidism (25%), hyperparathyroidism (15,6%) and hypogonadism (29% of male and 25.3% of female). Dysfunction of the hypothalamic-pituitary-thyroid axis occurred significantly more often in patients after combined chemoradiotherapy than in patients receiving chemotherapy only (χ2=9,4, р=0,002). We found that increased levels PTH was negatively correlated with BMD in the lumbar spine (r = -0,74, p = 0,00002) and in the femoral neck (r = -0,66, p = 0,0003). The men with HL had lower free testosterone than controls (p=0,04). However, LH and FSH levels in male with HL were elevated: p = 0,0004 and p = 0,04, respectively. Women of reproductive age with HL had higher levels of LH in the luteal phase (p = 0,05) and a higher levels of FSH in the follicular phase (p = 0,02) than controls.

Conclusion

The high prevalence of endocrine disorders in HL survivors demonstrates the necessity to develop screening programs for early treatment of endocrine pathology in patients with HL, as well as the participation of endocrinologists in the follow-up and treatment of this category of patients.                                                                                                                                  

Keyword(s): Hodgkin's lymphoma

By clicking “Accept Terms & all Cookies” or by continuing to browse, you agree to the storing of third-party cookies on your device to enhance your user experience and agree to the user terms and conditions of this learning management system (LMS).

Cookie Settings
Accept Terms & all Cookies